Skip to main content
IBRX
NASDAQ Life Sciences

ImmunityBio Q2 Revenue Hits $50.7M, Up 92% YoY; Cash at $357M

Tom Rudovsky · Reported by BusinessWire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$7.181
Mkt Cap
$7.489B
52W Low
$1.95
52W High
$12.43
52W Position info
268% above low
Off High info
42% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

IBRX has more than doubled off its 52-week low of $1.95.

Summary

ImmunityBio delivered record Q2 product revenue of $50.7 million, a 92% jump from last year and 15% above Q1. First-half revenue reached $94.8 million, already approaching the full-year 2025 total of $113 million. The company holds $357.4 million in cash, providing a solid runway for its expanding clinical pipeline. This marks the eighth straight quarter of sequential growth for ANKTIVA, now approved in five jurisdictions covering 34 countries. The strong top-line momentum and cash position stand out against a backdrop of ongoing legal challenges and a wider net loss driven by non-cash fair value adjustments. The revenue trajectory suggests ANKTIVA is gaining real commercial traction, which could shift the narrative from a cash-burning biotech to a sustainable commercial story.

Updates

  1. · SEC 8-K — Q2 net loss was $230.4 million, or $0.22 per share, compared with $92.6 million a year earlier. Adjusted net loss was $81.0 million, down from $89.9 million.

At the time of this announcement, IBRX was trading at $7.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.5B. The 52-week trading range was $1.95 to $12.43. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.


Price Chart

Share this article

Copied!

IBRX - Latest Insights

IBRX
Nov 09, 2026, 7:52 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $7.59
Real-time Price: $6.08 info
Change: -$1.51 (-20%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:39 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.09
Real-time Price: $6.08 info
Change: -$2.01 (-25%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 7:30 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $8.84
Real-time Price: $6.08 info
Change: -$2.76 (-31%) info
Market Cap: $6.404B info
IBRX
Nov 09, 2026, 6:30 AM EST
Source: BusinessWire
Importance Score:
8
Price at Filing: $8.76
Real-time Price: $6.08 info
Change: -$2.68 (-31%) info
Market Cap: $6.404B info
IBRX
Oct 16, 2026, 11:49 AM EDT
Source: BusinessWire
Importance Score:
7
Price at Filing: $9.42
Real-time Price: $6.08 info
Change: -$3.34 (-35%) info
Market Cap: $6.404B info